Fabry's disease

Journal of the Neurological Sciences

Volumn 344, Issue 1-2, 2014, Pages 5-19

  El Abassi, Rima ^a   Singhal, Divya ^a   England, John D ^a  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Enzyme replacement therapy; Fabry's disease; Hereditary neuropathy; Lysosomal storage disease; Painful neuropathy; Small fiber neuropathy

Indexed keywords

ALPHA GALACTOSIDASE; GLOBOTRIAOSYLCERAMIDE; GLYCOSPHINGOLIPID;

CLINICAL FEATURE; DISEASE SEVERITY; ENZYME REPLACEMENT; EPIDEMIC; FABRY DISEASE; GASTROINTESTINAL SYMPTOM; GENDER; GENE; GLA GENE; HEARING; HETEROZYGOTE; HUMAN; KIDNEY FUNCTION; NEUROPATHIC PAIN; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SYMPTOMATOLOGY; TRANSIENT ISCHEMIC ATTACK; COMPLICATION;

FABRY DISEASE; HUMANS;

EID: 84906935556     PISSN: 0022510X     EISSN: 18785883     Source Type: Journal    
DOI: 10.1016/j.jns.2014.06.029     Document Type: Review

References (294)

1. S. Ishii, R. Kase, H. Sakuraba, and Y. Suzuki Characterization of a mutant alpha-galactosidase gene product for the late-onset cardiac form of Fabry disease Biochem Biophys Res Commun 197 3 1993 1585 1589 (Epub 1993/12/30)
2. H. Sakuraba, A. Oshima, Y. Fukuhara, M. Shimmoto, Y. Nagao, and D.F. Bishop et al. Identification of point mutations in the alpha-galactosidase A gene in classical and atypical hemizygotes with Fabry disease Am J Hum Genet 47 5 1990 784 789 (Epub 1990/11/01)
3. M. Dutsch, H. Marthol, B. Stemper, M. Brys, T. Haendl, and M.J. Hilz Small fiber dysfunction predominates in Fabry neuropathy J Clin Neurophysiol 19 6 2002 575 586 (Epub 2002/12/19)
4. H.S. Bernstein, D.F. Bishop, K.H. Astrin, R. Kornreich, C.M. Eng, and H. Sakuraba et al. Fabry disease: six gene rearrangements and an exonic point mutation in the alpha-galactosidase gene J Clin Invest 83 4 1989 1390 1399 (Epub 1989/04/01)
5. M. Shimotori, H. Maruyama, G. Nakamura, T. Suyama, F. Sakamoto, and M. Itoh et al. Novel mutations of the GLA gene in Japanese patients with Fabry disease and their functional characterization by active site specific chaperone Hum Mutat 29 2 2008 331 (Epub 2008/01/22)
6. R. Kornreich, D.F. Bishop, and R.J. Desnick Alpha-galactosidase A gene rearrangements causing Fabry disease. Identification of short direct repeats at breakpoints in an Alu-rich gene J Biol Chem 265 16 1990 9319 9326 (Epub 1990/06/05)
7. S. Ishii, H.H. Chang, K. Kawasaki, K. Yasuda, H.L. Wu, and S.C. Garman et al. Mutant alpha-galactosidase A enzymes identified in Fabry disease patients with residual enzyme activity: biochemical characterization and restoration of normal intracellular processing by 1-deoxygalactonojirimycin Biochem J 406 2 2007 285 295 (Epub 2007/06/09)
8. U. Ramaswami, C. Whybra, R. Parini, G. Pintos-Morell, A. Mehta, and G. Sunder-Plassmann et al. Clinical manifestations of Fabry disease in children: data from the Fabry Outcome Survey Acta Paediatr 95 1 2006 86 92 (Epub 2006/02/28)
9. O.A. Bodamer, B. Johnson, and A. Dajnoki Diagnosing lysosomal storage disorders: Fabry disease. Current protocols in human genetics/editorial board, Jonathan L Haines [et al] 2013 (Chapter 17:Unit17 3. Epub 2013/04/19)
10. T. Lucke, W. Hoppner, E. Schmidt, S. Illsinger, and A.M. Das Fabry disease: reduced activities of respiratory chain enzymes with decreased levels of energy-rich phosphates in fibroblasts Mol Genet Metab 82 1 2004 93 97 (Epub 2004/04/28)
11. A.M. Das, and H.Y. Naim Biochemical basis of Fabry disease with emphasis on mitochondrial function and protein trafficking Adv Clin Chem 49 2009 57 71 (Epub 2009/12/02)
12. J.L. Park, L. Shu, and J.A. Shayman Differential involvement of COX1 and COX2 in the vasculopathy associated with the alpha-galactosidase A-knockout mouse Am J Physiol Heart Circ Physiol 296 4 2009 H1133 H1140 (Epub 2009/02/10)
13. S. Park, J.A. Kim, K.Y. Joo, S. Choi, E.N. Choi, and J.A. Shin et al. Globotriaosylceramide leads to K(Ca)3.1 channel dysfunction: a new insight into endothelial dysfunction in Fabry disease Cardiovasc Res 89 2 2011 290 299
14. J.S. Shen, X.L. Meng, D.F. Moore, J.M. Quirk, J.A. Shayman, and R. Schiffmann et al. Globotriaosylceramide induces oxidative stress and up-regulates cell adhesion molecule expression in Fabry disease endothelial cells Mol Genet Metab 95 3 2008 163 168 (Epub 2008/08/19)
15. M. Chevrier, N. Brakch, L. Celine, D. Genty, Y. Ramdani, and S. Moll et al. Autophagosome maturation is impaired in Fabry disease Autophagy 6 5 2010 589 599 (Epub 2010/05/01)
16. J.C. Moon, M. Sheppard, E. Reed, P. Lee, P.M. Elliott, and D.J. Pennell The histological basis of late gadolinium enhancement cardiovascular magnetic resonance in a patient with Anderson-Fabry disease J Cardiovasc Magn Reson 8 3 2006 479 482 (Epub 2006/06/08)
17. R. Torra Renal manifestations in Fabry disease and therapeutic options Kidney Int Suppl 111 2008 S29 S32 (Epub 2008/11/29)
18. C. Wanner Fabry disease model: a rational approach to the management of Fabry disease Clin Ther 29 Suppl. A 2007 S2 S5 (Epub 2007/12/06)
19. P.J. Meikle, J.J. Hopwood, A.E. Clague, and W.F. Carey Prevalence of lysosomal storage disorders JAMA 281 3 1999 249 254 (Epub 1999/01/26)
20. B.J. Poorthuis, R.A. Wevers, W.J. Kleijer, J.E. Groener, J.G. de Jong, and S. van Weely et al. The frequency of lysosomal storage diseases in The Netherlands Hum Genet 105 1-2 1999 151 156 (Epub 1999/09/10)
21. B. Hoffmann, and E. Mayatepek Fabry disease - often seen, rarely diagnosed Dtsch Arzteblatt Int 106 26 2009 440 447 (Epub 2009/07/23)
22. M. Spada, S. Pagliardini, M. Yasuda, T. Tukel, G. Thiagarajan, and H. Sakuraba et al. High incidence of later-onset Fabry disease revealed by newborn screening Am J Hum Genet 79 1 2006 31 40 (Epub 2006/06/15)
23. W.L. Hwu, Y.H. Chien, N.C. Lee, S.C. Chiang, R. Dobrovolny, and A.C. Huang et al. Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936 + 919G > A (IVS4 + 919G > A) Hum Mutat 30 10 2009 1397 1405
24. W.R. Wilcox, J.P. Oliveira, R.J. Hopkin, A. Ortiz, M. Banikazemi, and U. Feldt-Rasmussen et al. Females with Fabry disease frequently have major organ involvement: lessons from the Fabry registry Mol Genet Metab 93 2 2008 112 128 (Epub 2007/11/27)
25. K.D. MacDermot, A. Holmes, and A.H. Miners Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females J Med Genet 38 11 2001 769 775 (Epub 2001/12/06)
26. Germain DP. [Fabry disease. Clinical and genetic aspects. Therapeutic perspectives]. La Revue de medecine interne/fondee par la Societe nationale francaise de medecine interne. 2000;21(12):1086-103. Epub 2001/02/24. La maladie de Fabry. Aspects cliniques et genetiques. Perspectives therapeutiques.
27. C. Whybra, K. Wendrich, M. Ries, A. Gal, and M. Beck Clinical manifestation in female Fabry disease patients Contrib Nephrol 136 2001 245 250 (Epub 2001/11/02)
28. M.F. Lyon Gene action in the X-chromosome of the mouse (Mus musculus L.) Nature 190 1961 372 373
29. A. Fellgiebel, M.J. Muller, M. Mazanek, K. Baron, M. Beck, and P. Stoeter White matter lesion severity in male and female patients with Fabry disease Neurology 65 4 2005 600 602 (Epub 2005/08/24)
30. R.P. Grewal, and S.K. McLatchey Cerebrovascular manifestations in a female carrier of Fabry's disease Acta Neurol Belg 92 1 1992 36 40 (Epub 1992/01/01)
31. K. Wendrich, C. Whybra, M. Ries, A. Gal, and M. Beck Neurological manifestation of Fabry disease in females Contrib Nephrol 136 2001 241 244 (Epub 2001/11/02)
32. P.S. Giacomini, P.T. Shannon, J.T. Clarke, and C. Jaigobin Fabry's disease presenting as stroke in a young female Can J Neurol Sci 31 1 2004 112 114 (Epub 2004/03/25)
33. A. Linhart, T. Palecek, J. Bultas, J.J. Ferguson, J. Hrudova, and D. Karetova et al. New insights in cardiac structural changes in patients with Fabry's disease Am Heart J 139 6 2000 1101 1108 (Epub 2000/05/29)
34. C. Kampmann, F. Baehner, C. Whybra, C. Martin, C.M. Wiethoff, and M. Ries et al. Cardiac manifestations of Anderson-Fabry disease in heterozygous females J Am Coll Cardiol 40 9 2002 1668 1674 (Epub 2002/11/13)
35. A. Ortiz, J.P. Oliveira, S. Waldek, D.G. Warnock, B. Cianciaruso, and C. Wanner Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy Nephrol Dial Transplant 23 5 2008 1600 1607 (Epub 2008/01/08)
36. C. Wanner, J.P. Oliveira, A. Ortiz, M. Mauer, D.P. Germain, and G.E. Linthorst et al. Prognostic indicators of renal disease progression in adults with Fabry disease: natural history data from the Fabry registry Clin J Am Soc Nephrol 5 12 2010 2220 2228 (Epub 2010/09/04)
37. C.M. Eng, J. Fletcher, W.R. Wilcox, S. Waldek, C.R. Scott, and D.O. Sillence et al. Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry registry J Inherit Metab Dis 30 2 2007 184 192 (Epub 2007/03/10)
38. S. Popli, D.J. Leehey, Z.V. Molnar, Z.M. Nawab, and T.S. Ing Demonstration of Fabry's disease deposits in placenta Am J Obstet Gynecol 162 2 1990 464 465 (Epub 1990/02/01)
39. A.C. Vedder, A. Strijland, M.A. vd Bergh Weerman, S. Florquin, J.M. Aerts, and C.E. Hollak Manifestations of Fabry disease in placental tissue J Inherit Metab Dis 29 1 2006 106 111 (Epub 2006/04/08)
40. S.C. Garman Structure-function relationships in alpha-galactosidase A Acta Paediatr 96 2007 6 16 (Suppl.)
41. L. Van der Tol, B.E. Smid, B.J. Poorthuis, M. Biegstraaten, R.H. Deprez, and G.E. Linthorst et al. A systematic review on screening for Fabry disease: prevalence of individuals with genetic variants of unknown significance J Med Genet 51 2014 1 9
42. R.J. Hopkin, J. Bissler, M. Banikazemi, L. Clarke, C.M. Eng, and D.P. Germain et al. Characterization of Fabry disease in 352 pediatric patients in the Fabry registry Pediatr Res 64 5 2008 550 555 (Epub 2008/07/04)
43. A. Mehta, R. Ricci, U. Widmer, F. Dehout, A. Garcia de Lorenzo, and C. Kampmann et al. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey Eur J Clin Investig 34 3 2004 236 242
44. W. von Scheidt, C.M. Eng, T.F. Fitzmaurice, E. Erdmann, G. Hubner, and E.G. Olsen et al. An atypical variant of Fabry's disease with manifestations confined to the myocardium N Engl J Med 324 6 1991 395 399 (Epub 1991/02/07)
45. S. Nakao, T. Takenaka, M. Maeda, C. Kodama, A. Tanaka, and M. Tahara et al. An atypical variant of Fabry's disease in men with left ventricular hypertrophy N Engl J Med 333 5 1995 288 293 (Epub 1995/08/03)
46. S. Nakao, T. Takenaka, M. Maeda, C. Kodama, A. Tanaka, and M. Tahara et al. An atypical variant of Fabry's disease in men with left ventricular hypertrophy N Engl J Med 333 1995 288 293
47. M. Spada, S. Pagliardini, M. Yasuda, T. Tukel, G. Thiagarajan, H. Sakuraba, A. Ponzone, and R.J. Desnick High incidence of later-onset fabry disease revealed by newborn screening Am J Hum Genet 79 2006 31 40
48. D.P. Germain, S. Waldek, M. Banikazemi, D.A. Bushinsky, J. Charrow, and R.J. Desnick et al. Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease J Am Soc Nephrol 18 5 2007 1547 1557 (Epub 2007/04/06)
49. B.L. Thurberg, H. Rennke, R.B. Colvin, S. Dikman, R.E. Gordon, and A.B. Collins et al. Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy Kidney Int 62 6 2002 1933 1946 (Epub 2002/11/13)
50. J. Takanashi, A.J. Barkovich, W.P. Dillon, E.H. Sherr, K.A. Hart, and S. Packman T1 hyperintensity in the pulvinar: key imaging feature for diagnosis of Fabry disease AJNR Am J Neuroradiol 24 5 2003 916 921 (Epub 2003/05/16)
51. M. Elleder, V. Bradova, F. Smid, M. Budesinsky, K. Harzer, and B. Kustermann-Kuhn et al. Cardiocyte storage and hypertrophy as a sole manifestation of Fabry's disease. Report on a case simulating hypertrophic non-obstructive cardiomyopathy Virchows Arch 417 5 1990 449 455 (Epub 1990/01/01.42)
52. B. Sachdev, T. Takenaka, H. Teraguchi, C. Tei, P. Lee, and W.J. McKenna et al. Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy Circulation 105 12 2002 1407 1411 (Epub 2002/03/27)
53. L. Monserrat, J.R. Gimeno-Blanes, F. Marin, M. Hermida-Prieto, A. Garcia-Honrubia, and I. Perez et al. Prevalence of fabry disease in a cohort of 508 unrelated patients with hypertrophic cardiomyopathy J Am Coll Cardiol 50 25 2007 2399 2403 (Epub 2007/12/25)
54. B. Sachdev, T. Takenaka, H. Teraguchi, C. Tei, P. Lee, and W.J. McKenna et al. Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy Circulation 105 2002 1407 1411
55. L. Monserrat, J.R. Gimeno-Blanes, F. Marin, M. Hermida-Prieto, A. Garcia-Honrubia, and I. Perez et al. Prevalence of Fabry disease in a cohort of 508 unrelated patients with hypertrophic cardiomyopathy J Am Coll Cardiol 50 2007 2399 2403
56. A.A. Hagege, E. Caudron, T. Damy, R. Roudaut, A. Millaire, and C. Etchecopar-Chevreuil et al. Screening patients with hypertrophic cardiomyopathy for Fabry disease using a filter-paper test: the FOCUS study Heart 97 2 2011 131 136
57. S. Nakao, C. Kodama, T. Takenaka, A. Tanaka, Y. Yasumoto, and A. Yoshida et al. Fabry disease: detection of undiagnosed hemodialysis patients and identification of a "renal variant" phenotype Kidney Int 64 3 2003 801 807 (Epub 2003/08/13)
58. A. Rolfs, T. Bottcher, M. Zschiesche, P. Morris, B. Winchester, and P. Bauer et al. Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study Lancet 366 2005 1794 1796
59. R. Brouns, R. Sheorajpanday, E. Braxel, F. Eyskens, R. Baker, and D. Hughes et al. Middelheim Fabry Study (MiFaS): a retrospective Belgian study on the prevalence of Fabry disease in young patients with cryptogenic stroke Clin Neurol Neurosurg 109 2007 479 484
60. R. Brouns, V. Thijs, F. Eyskens, M. Van den Broeck, S. Belachew, and C. Van Broeckhoven et al. Belgian Fabry study: prevalence of Fabry disease in a cohort of 1000 young patients with cerebrovascular disease Stroke 41 2010 863 868
61. M.A. Wozniak, S.J. Kittner, S. Tuhrim, J.W. Cole, B. Stern, and M. Dobbins et al. Frequency of unrecognized Fabry disease among young European-American and African-American men with first ischemic stroke Stroke 41 2010 78 81
62. Y.H. Lien, L.W. Lai, and C.Y. Lui Unexpected diagnosis of fabry disease in an 80-year-old man with syncope Cardiology 96 2 2001 115 116
63. M. Biegstraaten, C.E.M. Hollak, M. Bakkers, C.G. Faber, J.M.F.G. Aerts, and I.N. van Schaik Small fiber neuropathy in Fabry disease Mol Genet Metab 106 2012 135 141
64. B.H. Lee, S.H. Heo, G.H. Kim, J.Y. Park, W.S. Kim, and D.H. Kang et al. Mutations of the GLA gene in Korean patients with Fabry disease and frequency of the E66Q allele as a functional variant in Korean newborns J Hum Genet 55 2010 512 517
65. E.M. Maier, S. Osterrieder, C. Whybra, M. Ries, A. Gal, and M. Beck et al. Disease manifestations and X inactivation in heterozygous females with Fabry disease Acta Paediatr Suppl 95 2006 30 38
66. K.D. MacDermot, A. Holmes, and A.H. Miners Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females J Med Genet 38 2001 769 775
67. 3 levels J Inherit Metab Dis 30 2007 68 78
68. D.P. Germain A new phenotype of Fabry disease with intermediate severity between the classical form and the cardiac variant Contrib Nephrol 136 2001 234 240
69. R. Rolke, R. Baron, C. Maier, T.R. Tolle, R.D. Treede, and A. Beyer et al. Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): standardized protocol and reference values Pain 123 3 2006 231 243 (Epub 2006/05/16)
70. R. Schiffmann Natural history of Fabry disease in males: preliminary observations J Inherit Metab Dis 24 Suppl. 2 2001 15 17 (discussion 1-2; Epub 2002/01/05)
71. R.S. Kocen, and P.K. Thomas Peripheral nerve involvement in Fabry's disease Arch Neurol 22 1 1970 81 88 (Epub 1970/01/01)
72. M.J. Hilz, B. Stemper, and E.H. Kolodny Lower limb cold exposure induces pain and prolonged small fiber dysfunction in Fabry patients Pain 84 2-3 2000 361 365 (Epub 2000/02/10)
73. S.M. Laaksonen, M. Roytta, S.K. Jaaskelainen, I. Kantola, M. Penttinen, and B. Falck Neuropathic symptoms and findings in women with Fabry disease Clin Neurophysiol 119 6 2008 1365 1372 (Epub 2008/04/05)
74. C.A. Luciano, J.W. Russell, T.K. Banerjee, J.M. Quirk, L.J. Scott, and J.M. Dambrosia et al. Physiological characterization of neuropathy in Fabry's disease Muscle Nerve 26 5 2002 622 629 (Epub 2002/10/29)
75. A. Torvin Moller, F. Winther Bach, U. Feldt-Rasmussen, A. Rasmussen, L. Hasholt, and H. Lan et al. Functional and structural nerve fiber findings in heterozygote patients with Fabry disease Pain 145 1-2 2009 237 245 (Epub 2009/08/12)
76. R. Maag, A. Binder, C. Maier, A. Scherens, T. Toelle, and R.D. Treede et al. Detection of a characteristic painful neuropathy in Fabry disease: a pilot study Pain Med 9 8 2008 1217 1223 (Epub 2008/06/21)
77. S.H. Morgan, P. Rudge, S.J. Smith, A.M. Bronstein, B.E. Kendall, and E. Holly et al. The neurological complications of Anderson-Fabry disease (alpha-galactosidase A deficiency) - investigation of symptomatic and presymptomatic patients Q J Med 75 277 1990 491 507 (Epub 1990/05/01)
78. M. Low, K. Nicholls, N. Tubridy, P. Hand, D. Velakoulis, and L. Kiers et al. Neurology of Fabry disease Intern Med J 37 7 2007 436 447 (Epub 2007/06/06)
79. A. Onishi, and P.J. Dyck Loss of small peripheral sensory neurons in Fabry disease. Histologic and morphometric evaluation of cutaneous nerves, spinal ganglia, and posterior columns Arch Neurol 31 2 1974 120 127
80. K. Toyooka, and G. Said Nerve biopsy findings in hemizygous and heterozygous patients with Fabry's disease J Neurol 244 7 1997 464 468
81. M. Valeriani, P. Mariotti, D. Le Pera, D. Restuccia, L. De Armas, and T. Maiese et al. Functional assessment of A delta and C fibers in patients with Fabry's disease Muscle Nerve 30 2004 708 713
82. N. Üçeyler, A.K. Kahn, D. Kramer, D. Zeller, J. Casanova-Molla, and C. Wanner et al. Impaired small fiber conduction in patients with Fabry disease: a neurophysiological case-control study BMC Neurol 13 2013 47
83. C.T. Shun, H.P. Wu, S.C. Hsieh, W.M. Lin, Y.H. Lin, and T.Y. Tai et al. Skin denervation in type 2 diabetes: correlations with diabetic duration and functional impairments Brain 127 2004 1593 1605
84. E. Vlckova-Moravcova, J. Bednarik, J. Belobradkova, and C. Sommer Small-fibre involvement in diabetic patients with neuropathic foot pain Diabet Med 25 2008 692 699
85. V. Heldestad, and E. Nordh Quantified sensory abnormalities in early genetically verified transthyretin amyloid polyneuropathy Muscle Nerve 35 2007 189 195
86. E.M. Kaye, E.H. Kolodny, E.L. Logigian, and M.D. Ullman Nervous system involvement in Fabry's disease: clinicopathological and biochemical correlation Ann Neurol 23 1988 505 509
87. R. Schiffmann, and L.J.C. Scott Pathophysiology and assessment of neuropathic pain in Fabry disease Acta Paediatr 439 2002 S48 S52
88. N. Geevasinga, M. Tchan, D. Sillence, and S. Vucic Upregulation of inward rectifying currents and Fabry disease neuropathy J Peripher Nerv Syst 17 2012 399 406
89. N. Üçeyler, L. He, D. Schönfeld, A.K. Kahn, K. Reiners, and M.J. Hilz et al. Small fibers in Fabry disease: baseline and follow-up data under enzyme replacement therapy J Peripher Nerv Syst 16 2011 304 314
90. J.M. Aerts, J.E. Groener, S. Kuiper, W.E. Donker-Koopman, A. Strijland, and R. Ottenhoff et al. Elevated globotriaosylsphingosine is a hallmark of Fabry disease Proc Natl Acad Sci U S A 105 2008 2812 2817
91. A. Penno, M.M. Reilly, H. Houlden, M. Laura, K. Rentsch, and V. Niederkofler et al. Hereditary sensory neuropathy type 1 is caused by the accumulation of two neurotoxic sphingolipids J Biol Chem 285 2010 11178 11187
92. H. Kaube, Z. Katsarava, T. Kaufer, H. Diener, and J. Ellrich A new method to increase nociception specificity of the human blink reflex Clin Neurophysiol 111 2000 413 416
93. Nurcan Üçeyler, Ann-Kathrin Kahn, Daniela Kramer, Daniel Zeller, Jordi Casanova-Molla, and Christoph Wanner et al. Impaired small fiber conduction in patients with Fabry disease: a neurophysiological case-control study BMC Neurol 13 2013 47
94. Luciano, Russell, Banerjee, Quirk, Scott, and Dambrosia Physiological characterization of neuropathy in Fabry's disease Muscle Nerve 26 5 2002 622 62959
95. R. Liguori, V. Di Stasi, E. Bugiardini, R. Mignani, A. Burlina, and W. Borsini et al. Small fiber neuropathy in female patients with fabry disease Muscle Nerve 41 3 2010 409 412
96. L.J. Scott, J.W. Griffin, C. Luciano, N.W. Barton, T. Banerjee, and T. Crawford et al. Quantitative analysis of epidermal innervation in Fabry disease Neurology 52 6 1999 1249 1254
97. F. Gemignani, A. Marbini, M.M. Bragaglia, and E. Govoni Pathological study of the sural nerve in Fabry's disease Eur Neurol 23 1984 173 181
98. W.R. Kennedy Unmyelinated nerves, challenges, and opportunities: skin biopsy and beyond Suppl Clin Neurophysiol 57 2004 8 14
99. Nurcan Üçeyler, Lan He, Dorothee Schönfeld, Ann-Kathrin Kahn, Karlheinz Reiners, and Max J. Hilz et al. Small fibers in Fabry disease: baseline and follow-up data under enzyme replacement therapy J Peripher Nerv Syst 16 2011 304 314
100. L.J. Scott, J.W. Griffin, C. Luciano, N.W. Barton, T. Banerjee, and T. Crawford et al. Quantitative analysis of epidermal innervation in Fabry disease Neurology 52 1999 1249 1254
101. B. Hoffmann, M. Beck, G. Sunder-Plassmann, W. Borsini, R. Ricci, and A. Mehta Nature and prevalence of pain in Fabry disease and its response to enzyme replacement therapy - a retrospective analysis from the Fabry Outcome Survey Clin J Pain 23 6 2007 535 542 (Epub 2007/06/19)
102. J. Charrow A 14-year-old boy with pain in hands and feet Pediatr Ann 38 4 2009 190 (2. Epub 2009/05/22)
103. R. Schiffmann, and L.J. Scott Pathophysiology and assessment of neuropathic pain in Fabry disease Acta Paediatr Suppl 91 439 2002 48 52 (Epub 2003/02/08)
104. E.H. Kolodny, and G.M. Pastores Anderson-Fabry disease: extrarenal, neurologic manifestations J Am Soc Nephrol 13 2002 S3 S150
105. A.N. Rahman, F.A. Simeone, D.B. Hackel, P.W. Hall, E.Z. Hirsch, and J.W. Harris Angiokeratoma corporis diffusum universale (hereditary dystopic lipidosis) Trans Assoc Am Phys 74 1971 366 377
106. A.J. McDougall, and J.G. McLeod Autonomic neuropathy, I. Clinical features, investigation, pathophysiology, and treatment J Neurol Sci 137 2 1996 79 88
107. M. Donaghy, R.N. Hakin, J.M. Bamford, A. Garner, G.R. Kirkby, and B.A. Noble et al. Hereditary sensory neuropathy with neurotrophic keratitis. Description of an autosomal recessive disorder with a selective reduction of small myelinated nerve fibres and a discussion of the classification of the hereditary sensory neuropathies Brain 110 Pt 3 1987 563 583 (Epub 1987/06/01)
108. W.J. Cable, E.H. Kolodny, and R.D. Adams Fabry disease: impaired autonomic function Neurology 32 5 1982 498 502 (Epub 1982/05/01)
109. N. Fukuhara, M. Suzuki, N. Fujita, and T. Tsubaki Fabry's disease on the mechanism of the peripheral nerve involvement Acta Neuropathol 33 1 1975 9 21 (Epub 1975/10/27)
110. K. Yamamoto, G. Sobue, S. Iwase, K. Kumazawa, T. Mitsuma, and T. Mano Possible mechanism of anhidrosis in a symptomatic female carrier of Fabry's disease: an assessment by skin sympathetic nerve activity and sympathetic skin response Clin Auton Res 6 2 1996 107 110 (Epub 1996/04/01)
111. L.M. Lao, M. Kumakiri, H. Mima, H. Kuwahara, H. Ishida, and K. Ishiguro et al. The ultrastructural characteristics of eccrine sweat glands in a Fabry disease patient with hypohidrosis J Dermatol Sci 18 2 1998 109 117 (Epub 1998/12/02)
112. R. Schiffmann, J.B. Kopp, H.A. Austin III, S. Sabnis, D.F. Moore, and T. Weibel et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial JAMA 285 21 2001 2743 2749 (Epub 2001/06/21)
113. G. Altarescu, D.F. Moore, R. Pursley, U. Campia, S. Goldstein, and M. Bryant et al. Enhanced endothelium-dependent vasodilation in Fabry disease Stroke 32 7 2001 1559 1562 (Epub 2001/07/07)
114. C. Kampmann, C.M. Wiethoff, C. Whybra, F.A. Baehner, E. Mengel, and M. Beck Cardiac manifestations of Anderson-Fabry disease in children and adolescents Acta Paediatr 97 4 2008 463 469 (Epub 2008/03/28)
115. Marieke Biegstraaten, Ivo N. van Schaik, Wouter Wieling, Frits A. Wijburg, and Carla EM Hollak Autonomic neuropathy in Fabry disease: a prospective study using the Autonomic Symptom Profile and cardiovascular autonomic function tests BMC Neurol 10 2010 38 (Epub 2001/12/12.)
116. Y.H. Lien, L.W. Lai, and C.Y. Lui Unexpected diagnosis of fabry disease in an 80-year-old man with syncope Cardiology 96 2 2001 115 116 (Epub 2001/12/12)
117. T. Mutoh, Y. Senda, K. Sugimura, Y. Koike, Y. Matsuoka, and I. Sobue et al. Severe orthostatic hypotension in a female carrier of Fabry's disease Arch Neurol 45 4 1988 468 472 (Epub 1988/04/01)
118. M. Biegstraaten, C.E. Hollak, M. Bakkers, C.G. Faber, J.M. Aerts, and I.N. van Schaik Small fiber neuropathy in Fabry disease Mol Genet Metab 106 2 2012 135 141 (Epub 2012/04/14)
119. M.F. Mendez, T.M. Stanley, N.M. Medel, Z. Li, and D.T. Tedesco The vascular dementia of Fabry's disease Dement Geriatr Cogn Disord 8 4 1997 252 257 (Epub 1997/07/01)
120. R. Okeda, and M. Nisihara An autopsy case of Fabry disease with neuropathological investigation of the pathogenesis of associated dementia Neuropathology 28 5 2008 532 540 (Epub 2008/04/16)
121. K. Sims, J. Politei, M. Banikazemi, and P. Lee Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: natural history data from the Fabry registry Stroke 40 3 2009 788 794 (Epub 2009/01/20)
122. M.R. Patel, F. Cecchi, and M. Cizmarik et al. Cardiovascular events in patients with Fabry disease: natural history data from the Fabry registry J Am Coll Cardiol 57 2011 1093 1099
123. M.V. Baptista, S. Ferreira, E.M.T. Pinho, M. Carvalho, V.T. Cruz, and C. Carmona et al. Mutations of the GLA gene in young patients with stroke: the PORTYSTROKE study - screening genetic conditions in Portuguese young stroke patients Stroke 41 3 2010 431 436 (Epub 2010/01/30)
124. A. Rolfs, T. Bottcher, M. Zschiesche, P. Morris, B. Winchester, and P. Bauer et al. Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study Lancet 366 9499 2005 1794 1796 (Epub 2005/11/22)
125. M.A. Wozniak, S.J. Kittner, S. Tuhrim, J.W. Cole, B. Stern, and M. Dobbins et al. Frequency of unrecognized Fabry disease among young European-American and African-American men with first ischemic stroke Stroke 41 1 2010 78 81 (Epub 2009/12/17)
126. R. Brouns, V. Thijs, F. Eyskens, M. Van den Broeck, S. Belachew, and C. Van Broeckhoven et al. Belgian Fabry study: prevalence of Fabry disease in a cohort of 1000 young patients with cerebrovascular disease Stroke 41 5 2010 863 868 (Epub 2010/04/03)
127. A. Rolfs, F. Fazekas, U. Grittner, M. Dichgans, P. Martus, and M. Holzhausen et al. Acute cerebrovascular disease in the young: the Stroke in Young Fabry Patients study Stroke 44 2 2013 340 349
128. F1. Fazekas, C. Enzinger, R. Schmidt, M. Dichgans, B. Gaertner, and G.J. Jungehulsing et al. MRI in acute cerebral ischemia of the young: the Stroke in Young Fabry Patients (sifap1) study Neurology 26 22 2013 1914 1921 (81)
129. P. Mitsias, and S.R. Levine Cerebrovascular complications of Fabry's disease Ann Neurol 40 1 1996 8 17 (Epub 1996/07/01)
130. F.D. Testai, and P.B. Gorelick Inherited metabolic disorders and stroke part 1: Fabry disease and mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes Arch Neurol 67 1 2010 19 24 (Epub 2010/01/13)
131. A. Fellgiebel, M.J. Muller, and L. Ginsberg CNS manifestations of Fabry's disease Lancet Neurol 5 9 2006 791 795 (Epub 2006/08/18)
132. S.M. Rombach, T.B. Twickler, J.M. Aerts, G.E. Linthorst, F.A. Wijburg, and C.E. Hollak Vasculopathy in patients with Fabry disease: current controversies and research directions Mol Genet Metab 99 2 2010 99 108
133. J.M. Aerts, J.E. Groener, S. Kuiper, W.E. Donker-Koopman, A. Strijland, and R. Ottenhoff et al. Elevated globotriaosylsphingosine is a hallmark of Fabry disease Proc Natl Acad Sci U S A 105 8 2008 2812 2817 (Epub 2008/02/22)
134. D.T. Eitzman, P.F. Bodary, Y. Shen, C.G. Khairallah, S.R. Wild, and A. Abe et al. Fabry disease in mice is associated with age-dependent susceptibility to vascular thrombosis J Am Soc Nephrol 14 2 2003 298 302 (Epub 2003/01/23)
135. L. Shu, H.S. Murphy, L. Cooling, and J.A. Shayman An in vitro model of Fabry disease J Am Soc Nephrol 16 9 2005 2636 2645 (Epub 2005/07/22)
136. Y. Shen, P.F. Bodary, F.B. Vargas, J.W. Homeister, D. Gordon, and K.A. Ostenso et al. Alpha-galactosidase A deficiency leads to increased tissue fibrin deposition and thrombosis in mice homozygous for the factor V Leiden mutation Stroke 37 4 2006 1106 1108 (Epub 2006/03/04)
137. A. Rolfs, P. Martus, P.U. Heuschmann, U. Grittner, M. Holzhausen, and T. Tatlisumak et al. Protocol and methodology of the Stroke in Young Fabry Patients (sifap1) study: a prospective multicenter European study of 5024 young stroke patients aged 18-55 years Cerebrovasc Dis 31 3 2011 253 262 (Epub 2010/12/24; Epub 2009/11/11)
138. D.F. Moore, M.P. Gelderman, S.R. Fuhrmann, R. Schiffmann, R.O. Brady, and E. Goldin Fabry disease and vascular risk factors: future strategies for patient-based studies and the knockout murine model Acta Paediatr Suppl 95 451 2006 69 71 (Epub 2006/05/25)
139. P.F. Bodary, Y. Shen, F.B. Vargas, X. Bi, K.A. Ostenso, and S. Gu et al. Alpha-galactosidase A deficiency accelerates atherosclerosis in mice with apolipoprotein E deficiency Circulation 111 5 2005 629 632 (Epub 2005/01/26)
140. A. Fellgiebel, I. Keller, D. Marin, M.J. Muller, I. Schermuly, and I. Yakushev et al. Diagnostic utility of different MRI and MR angiography measures in Fabry disease Neurology 72 1 2009 63 68 (Epub 2009/01/06)
141. D.F. Moore, C.R. Kaneski, H. Askari, and R. Schiffmann The cerebral vasculopathy of Fabry disease J Neurol Sci 257 1-2 2007 258 263 (Epub 2007/03/17)
142. T. DeGraba, S. Azhar, F. Dignat-George, E. Brown, B. Boutiere, and G. Altarescu et al. Profile of endothelial and leukocyte activation in Fabry patients Ann Neurol 47 2 2000 229 233 (Epub 2000/02/09)
143. D.F. Moore, L.T. Scott, M.T. Gladwin, G. Altarescu, C. Kaneski, and K. Suzuki et al. Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease: reversal by enzyme replacement therapy Circulation 104 13 2001 1506 1512 (Epub 2001/09/26)
144. K. Demuth, and D.P. Germain Endothelial markers and homocysteine in patients with classic Fabry disease Acta Paediatr Suppl 91 439 2002 57 61 (Epub 2003/02/08)
145. M.J. Hilz, E.H. Kolodny, M. Brys, B. Stemper, T. Haendl, and H. Marthol Reduced cerebral blood flow velocity and impaired cerebral autoregulation in patients with Fabry disease J Neurol 251 5 2004 564 570 (Epub 2004/05/28)
146. D.F. Moore, G. Altarescu, G.S. Ling, N. Jeffries, K.P. Frei, and T. Weibel et al. Elevated cerebral blood flow velocities in Fabry disease with reversal after enzyme replacement Stroke 33 2 2002 525 531 (Epub 2002/02/02)
147. E.H. Kolodny, and G.M. Pastores Anderson-Fabry disease: extrarenal, neurologic manifestations J Am Soc Nephrol 13 Suppl. 2 2002 S150 S153 (Epub 2002/06/18)
148. L. Jardim, L. Vedolin, I.V. Schwartz, M.G. Burin, C. Cecchin, and L. Kalakun et al. CNS involvement in Fabry disease: clinical and imaging studies before and after 12 months of enzyme replacement therapy J Inherit Metab Dis 27 2 2004 229 240 (Epub 2004/05/26)
149. A.P. Burlina, R. Manara, C. Caillaud, J.P. Laissy, M. Severino, and I. Klein et al. The pulvinar sign: frequency and clinical correlations in Fabry disease J Neurol 255 5 2008 738 744 (Epub 2008/02/26)
150. D.F. Moore, F. Ye, R. Schiffmann, and J.A. Butman Increased signal intensity in the pulvinar on T1-weighted images: a pathognomonic MR imaging sign of Fabry disease AJNR Am J Neuroradiol 24 6 2003 1096 1101 (Epub 2003/06/19)
151. J. Takanashi, A.J. Barkovich, W.P. Dillon, E.H. Sherr, K.A. Hart, and S. Packman T1 hyperintensity in the pulvinar: key imaging feature for diagnosis of Fabry disease AJNR Am J Neuroradiol 24 5 2003 916 921 (Epub 2003/05/16)
152. S. Buechner, M. Moretti, A.P. Burlina, G. Cei, R. Manara, and R. Ricci et al. Central nervous system involvement in Anderson-Fabry disease: a clinical and MRI retrospective study J Neurol Neurosurg Psychiatry 79 11 2008 1249 1254 (Epub 2008/06/07)
153. D.P. Germain, K. Benistan, and P. Halimi Chiari type I malformation in four unrelated patients affected with Fabry disease Eur J Med Genet 49 5 2006 419 425 (Epub 2006/03/03)
154. G. Tedeschi, S. Bonavita, T.K. Banerjee, A. Virta, and R. Schiffmann Diffuse central neuronal involvement in Fabry disease: a proton MRS imaging study Neurology 52 8 1999 1663 1667 (Epub 1999/05/20)
155. D.P. Germain, P. Avan, A. Chassaing, and P. Bonfils Patients affected with Fabry disease have an increased incidence of progressive hearing loss and sudden deafness: an investigation of twenty-two hemizygous male patients BMC Med Genet 3 2002 10 (Epub 2002/10/16)
156. A. Palla, S. Hegemann, U. Widmer, and D. Straumann Vestibular and auditory deficits in Fabry disease and their response to enzyme replacement therapy J Neurol 254 10 2007 1433 1442 (Epub 2007/10/16)
157. M. Ries, H.J. Kim, C.K. Zalewski, M.A. Mastroianni, D.F. Moore, and R.O. Brady et al. Neuropathic and cerebrovascular correlates of hearing loss in Fabry disease Brain 130 Pt 1 2007 143 150 (Epub 2006/11/16)
158. M.C. Gubler, G. Lenoir, J.P. Grunfeld, A. Ulmann, D. Droz, and R. Habib Early renal changes in hemizygous and heterozygous patients with Fabry's disease Kidney Int 13 3 1978 223 235 (Epub 1978/03/01)
159. A. Sessa, M. Meroni, G. Battini, A. Maglio, P.L. Brambilla, and M. Bertella et al. Renal pathological changes in Fabry disease J Inherit Metab Dis 24 Suppl. 2 2001 66 70 (discussion 65; Epub 2002/01/05)
160. J.P. Grunfeld, O. Lidove, D. Joly, and F. Barbey Renal disease in Fabry patients J Inherit Metab Dis 24 Suppl. 2 2001 71 74 (discussion 65; Epub 2002/01/05)
161. A.B. Fogo, L. Bostad, E. Svarstad, W.J. Cook, S. Moll, and F. Barbey et al. Scoring system for renal pathology in Fabry disease: report of the International Study Group of Fabry Nephropathy (ISGFN) Nephrol Dial Transplant 25 7 2010 2168 2177 (Epub 2009/10/17)
162. N. Gadoth, and U. Sandbank Involvement of dorsal root ganglia in Fabry's disease J Med Genet 20 4 1983 309 312 (Epub 1983/08/01)
163. I. Hozumi, M. Nishizawa, T. Ariga, Y. Inoue, Y. Ohnishi, and A. Yokoyama et al. Accumulation of glycosphingolipids in spinal and sympathetic ganglia of a symptomatic heterozygote of Fabry's disease J Neurol Sci 90 3 1989 273 280 (Epub 1989/05/01)
164. F. Gemignani, A. Marbini, M.M. Bragaglia, and E. Govoni Pathological study of the sural nerve in Fabry's disease Eur Neurol 23 3 1984 173 181 (Epub 1984/01/01)
165. P. Boutouyrie, S. Laurent, B. Laloux, O. Lidove, J.P. Grunfeld, and D.P. Germain Non-invasive evaluation of arterial involvement in patients affected with Fabry disease J Med Genet 38 9 2001 629 631 (Epub 2001/09/22)
166. P. Boutouyrie, S. Laurent, B. Laloux, O. Lidove, J.P. Grunfeld, and D.P. Germain Arterial remodelling in Fabry disease Acta Paediatr Suppl 91 439 2002 62 66 (Epub 2003/02/08)
167. B.R. Amann-Vesti, G. Gitzelmann, U. Widmer, N.U. Brosshard, B. Steinmann, and R. Koppensteiner Severe lymphatic microangiopathy in Fabry disease Lymphat Res Biol 1 2003 185 189
168. F. Barbey, N. Brakch, A. Linhart, X. Jeanrenaud, T. Palecek, and J. Bultas et al. Increased carotid intima-media thickness in the absence of atherosclerotic plaques in an adult population with Fabry disease Acta Paediatr Suppl 95 451 2006 63 68 (Epub 2006/05/25)
169. R. Schiffmann, D.G. Warnock, M. Banikazemi, J. Bultas, G.E. Linthorst, and S. Packman et al. Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy Nephrol Dial Transplant 24 7 2009 2102 2111 (Epub 2009/02/17)
170. M. Senechal, and D.P. Germain Fabry disease: a functional and anatomical study of cardiac manifestations in 20 hemizygous male patients Clin Genet 63 1 2003 46 52 (Epub 2003/01/10)
171. A. Linhart, C. Kampmann, J.L. Zamorano, G. Sunder-Plassmann, M. Beck, and A. Mehta et al. Cardiac manifestations of Anderson-Fabry disease: results from the International Fabry Outcome Survey Eur Heart J 28 10 2007 1228 1235 (Epub 2007/05/08)
172. B. Sachdev, T. Takenaka, H. Teraguchi, C. Tei, P. Lee, and W.J. McKenna Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy Circulation 105 12 2002 1407 1411
173. P.M. Elliott, H. Kindler, J.S. Shah, B. Sachdev, O.E. Rimoldi, and R. Thaman et al. Coronary microvascular dysfunction in male patients with Anderson-Fabry disease and the effect of treatment with alpha galactosidase A Heart 92 3 2006 357 360 (Epub 2005/08/09)
174. R.J. Kalliokoski, K.K. Kalliokoski, J. Sundell, E. Engblom, M. Penttinen, and I. Kantola et al. Impaired myocardial perfusion reserve but preserved peripheral endothelial function in patients with Fabry disease J Inherit Metab Dis 28 4 2005 563 573 (Epub 2005/05/20)
175. H. Hasegawa, H. Takano, S. Shindo, S. Takeda, N. Funabashi, and K. Nakagawa et al. Images in cardiovascular medicine. Transition from left ventricular hypertrophy to massive fibrosis in the cardiac variant of Fabry disease Circulation 113 16 2006 e720 e721 (Epub 2006/04/26)
176. T. Takenaka, H. Teraguchi, A. Yoshida, S. Taguchi, K. Ninomiya, and Y. Umekita et al. Terminal stage cardiac findings in patients with cardiac Fabry disease: an electrocardiographic, echocardiographic, and autopsy study J Cardiol 51 1 2008 50 59 (Epub 2008/06/05)
177. C. Orssaud, J. Dufier, and D. Germain Ocular manifestations in Fabry disease: a survey of 32 hemizygous male patients Ophthalmic Genet 24 3 2003 129 139 (Epub 2003/07/18)
178. A. Sodi, A.S. Ioannidis, A. Mehta, C. Davey, M. Beck, and S. Pitz Ocular manifestations of Fabry's disease: data from the Fabry Outcome Survey Br J Ophthalmol 91 2 2007 210 214 (Epub 2006/09/16)
179. T.T. Nguyen, T. Gin, K. Nicholls, M. Low, J. Galanos, and A. Crawford Ophthalmological manifestations of Fabry disease: a survey of patients at the Royal Melbourne Fabry Disease Treatment Centre Clin Exp Ophthalmol 33 2 2005 164 168 (Epub 2005/04/06)
180. N.A. Sher, R.D. Letson, and R.J. Desnick The ocular manifestations in Fabry's disease Arch Ophthalmol 97 4 1979 671 676 (Epub 1979/04/01)
181. G. Bierer, N. Kamangar, D. Balfe, W.R. Wilcox, and Z. Mosenifar Cardiopulmonary exercise testing in Fabry disease Respiration 72 5 2005 504 511 (Epub 2005/10/08)
182. S. Magage, J.C. Lubanda, D.P. Germain, J. Bultas, D. Karetova, and A. Linhart Respiratory involvement in patients with Fabry disease Atteinte respiratoire de la maladie de Fabry Med Sci 21 11 Suppl. 2005 37 39 (Epub 2005/12/06)
183. S. Magage, J.C. Lubanda, Z. Susa, J. Bultas, D. Karetova, and R. Dobrovolny et al. Natural history of the respiratory involvement in Anderson-Fabry disease J Inherit Metab Dis 30 5 2007 790 799 (Epub 2007/07/11)
184. D.P. Germain, K. Benistan, L. Khatchikian, and C. Mutschler Bone involvement in Fabry disease Atteinte osseuse de la maladie de Fabry Med Sci 21 11 Suppl. 2005 43 44 (Epub 2005/12/06)
185. D.P. Germain, K. Benistan, P. Boutouyrie, and C. Mutschler Osteopenia and osteoporosis: previously unrecognized manifestations of Fabry disease Clin Genet 68 1 2005 93 95 (Epub 2005/06/15)
186. H. Mersebach, J.O. Johansson, A.K. Rasmussen, B.A. Bengtsson, K. Rosenberg, and L. Hasholt et al. Osteopenia: a common aspect of Fabry disease. Predictors of bone mineral density Genet Med 9 12 2007 812 818 (Epub 2007/12/20)
187. J.S. Mayes, J.B. Scheerer, R.N. Sifers, and M.L. Donaldson Differential assay for lysosomal alpha-galactosidases in human tissues and its application to Fabry's disease Clin Chim Acta 112 2 1981 247 251 (Epub 1981/05/05)
188. B. Hoffmann, H. Georg Koch, S. Schweitzer-Krantz, U. Wendel, and E. Mayatepek Deficient alpha-galactosidase A activity in plasma but no Fabry disease - a pitfall in diagnosis Clin Chem Lab Med 43 11 2005 1276 1277 (Epub 2005/10/20)
189. N.A. Chamoles, M. Blanco, and D. Gaggioli Fabry disease: enzymatic diagnosis in dried blood spots on filter paper Clin Chim Acta 308 1-2 2001 195 196 (Epub 2001/07/04)
190. E. Caudron, D. Moliere, J.Y. Zhou, P. Prognon, and D.P. Germain Recent advances of Fabry disease screening for at risk population Avancees recentes dans le depistage de la maladie de Fabry pour les populations a risque Med Sci 21 11 Suppl. 2005 48 50 (Epub 2005/12/06)
191. Z. Lukacs, A. Keil, A. Kohlschutter, M. Beck, and E. Mengel The ratio of alpha-galactosidase to beta-glucuronidase activities in dried blood for the identification of female Fabry disease patients J Inherit Metab Dis 28 5 2005 803 805 (Epub 2005/09/10)
192. X.K. Zhang, C.S. Elbin, W.L. Chuang, S.K. Cooper, C.A. Marashio, and C. Beauregard et al. Multiplex enzyme assay screening of dried blood spots for lysosomal storage disorders by using tandem mass spectrometry Clin Chem 54 10 2008 1725 1728 (Epub 2008/08/23)
193. P. Olivova, K. van der Veen, E. Cullen, M. Rose, X.K. Zhang, and K.B. Sims et al. Effect of sample collection on alpha-galactosidase A enzyme activity measurements in dried blood spots on filter paper Clin Chim Acta 403 1-2 2009 159 162 (Epub 2009/02/28)
194. C. Flangea, C. Mosoarca, C. Cozma, M. Galusca, M. Przybylski, and A.D. Zamfir Testing the feasibility of fully automated chip-based nanoelectrospray ionization mass spectrometry as a novel tool for rapid diagnosis of Fabry disease Electrophoresis 34 11 2013 1572 1580 (Epub 2013/03/14.166)
195. P. Gaspar, J. Herrera, D. Rodrigues, S. Cerezo, R. Delgado, and C.F. Andrade et al. Frequency of Fabry disease in male and female haemodialysis patients in Spain BMC Med Genet 1 11 2010 19
196. D.P. Germain, K. Benistan, and L. Angelova X-linked inheritance and its implication in the diagnosis and management of female patients in Fabry disease La Revue de medecine interne/fondee par la Societe nationale francaise de medecine interne 31 (Suppl. 2) 2010 S209 S213 (Epub 2011/01/08.168)
197. Andreas Gal, A. Derralynn, and Hughes Bryan Winchester Toward a consensus in the laboratory diagnostics of Fabry disease - recommendations of a European expert group J Inherit Metab Dis 34 2 2011 509 514
198. Newborn screening M. Spada, S. Pagliardini, M. Yasuda, T. Tukel, G. Thiagarajan, H. Sakuraba, A. Ponzone, and R.J. Desnick High incidence of later-onset fabry disease revealed by newborn screening Am J Hum Genet 79 2006 31 40
199. M. Spada, S. Pagliardini, M. Yasuda, T. Tukel, G. Thiagarajan, H. Sakuraba, A. Ponzone, and R.J. Desnick High incidence of later-onset fabry disease revealed by newborn screening Am J Hum Genet 79 2006 31 40
200. C. Auray-Blais, D. Cyr, K. Mills, R. Giguere, and R. Drouin Development of a filter paper method potentially applicable to mass and high-risk urinary screenings for Fabry disease J Inherit Metab Dis 30 1 2007 106 (Epub 2006/12/16)
201. E. Young, K. Mills, P. Morris, A. Vellodi, P. Lee, and S. Waldek et al. Is globotriaosylceramide a useful biomarker in Fabry disease? Acta Paediatr Suppl 94 447 2005 51 54 (discussion 37-8; Epub 2005/05/18)
202. J. Andrade, P.J. Waters, R.S. Singh, A. Levin, B.C. Toh, and H.D. Vallance et al. Screening for Fabry disease in patients with chronic kidney disease: limitations of plasma alpha-galactosidase assay as a screening test Clin J Am Soc Nephrol 3 1 2008 139 145 (Epub 2007/11/16)
203. 3 levels J Inherit Metab Dis 30 1 2007 68 78 (Epub 2007/02/27)
204. Johannes M. Aerts, Johanna E. Groener, Sijmen Kuiper, Wilma E. Donker-Koopman, Anneke Trijland, and Roelof Ottenhoff et al. Elevated globotriaosylsphingosine is a hallmark of Fabry disease PNAS 105 8 2008 2812 2817 (Epub 2008/02/2008)
205. A.L. Oaklander, and M.M. Klein Evidence of small-fiber polyneuropathy in unexplained, juvenile-onset, widespread pain syndromes Pediatrics 131 4 2013 e1091 e1100 (Epub 2013/03/13.173)
206. T. Böttcher, A. Rolfs, C. Tanislav, A. Bitsch, W. Köhler, and J. Gaedeke et al. Fabry disease - underestimated in the differential diagnosis of multiple sclerosis? PLoS ONE 28 8 2013 e71894 10.1371/journal.pone.0071894
207. I.E. Knol, M.G. Ausems, D. Lindhout, O.P. van Diggelen, H. Verwey, and J. Davies et al. Different phenotypic expression in relatives with fabry disease caused by a W226X mutation Am J Med Genet 82 5 1999 436 439
208. R. Schiffmann, M. Ries, M. Timmons, J.T. Flaherty, and R.O. Brady Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting Nephrol Dial Transplant 21 2 2006 345 354 (Epub 2005/10/06)
209. J.E. Wraith, A. Tylki-Szymanska, N. Guffon, Y.H. Lien, M. Tsimaratos, and A. Vellodi et al. Safety and efficacy of enzyme replacement therapy with agalsidase beta: an international, open-label study in pediatric patients with Fabry disease J Pediatr 152 4 2008 563 570 (70 e1, Epub 2008/03/19.173)
210. A.C. Vedder, G.E. Linthorst, G. Houge, J.E. Groener, E.E. Ormel, and J. Berto et al. Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg PLoS ONE 2 7 2007 598 (Epub 2007/07/11)
211. K. Lee, X. Jin, K. Zhang, L. Copertino, L. Andrews, and J. Baker-Malcolm et al. A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease Glycobiology 13 4 2003 305 313 (Epub 2003/03/11)
212. H. Sakuraba, M. Murata-Ohsawa, I. Kawashima, Y. Tajima, M. Kotani, and T. Ohshima et al. Comparison of the effects of agalsidase alfa and agalsidase beta on cultured human Fabry fibroblasts and Fabry mice J Hum Genet 51 3 2006 180 188 (Epub 2005/12/24)
213. A.C. Vedder, G.E. Linthorst, G. Houge, J.E. Groener, E.E. Ormel, and B.J. Bouma et al. Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg PLoS ONE 2 7 2007 e598 (Epub 2007/07/12.182)
214. A. Mehta, M.L. West, A. Mehta, M.L. West, and G. Pintos-Morellorell et al. Therapeutic goals in the treatment of Fabry disease Genet Med 12 2010 713 720
215. R.J. Desnick, R. Brady, J. Barranger, A.J. Collins, D.P. Germain, and M. Goldman et al. Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy Ann Intern Med 138 4 2003 338 346 (Epub 2003/02/15)
216. R.M. Schaefer, A. Tylki-Szymanska, and M.J. Hilz Enzyme replacement therapy for Fabry disease: a systematic review of available evidence Drugs 69 16 2009 2179 2205 (Epub 2009/10/27)
217. C. Kampmann, A. Linhart, R.B. Devereux, and R. Schiffmann Effect of agalsidase alfa replacement therapy on Fabry disease-related hypertrophic cardiomyopathy: a 12- to 36-month, retrospective, blinded echocardiographic pooled analysis Clin Ther 9 1966-76 183
218. Dawn A. Laney, Robin L. Bennett, Virginia Clarke, Angela Fox, Robert J. Hopkin, and Jack Johnson et al. Fabry disease practice guidelines: recommendations of the National Society of Genetic Counselors J Genet Couns 22 5 2013 555 564
219. A. Sessa, M. Meroni, G. Battini, M. Righetti, M. Nebuloni, A. Tosoni, and G.L. Vago Evolution of renal pathology in Fabry disease Acta Paediatr Suppl 443 2003 6 (Epub 2007/01/02)
220. N. Uceyler, L. He, D. Schonfeld, A.K. Kahn, K. Reiners, and M.J. Hilz et al. Small fibers in Fabry disease: baseline and follow-up data under enzyme replacement therapy J Peripher Nerv Syst 16 4 2011 304 314 (Epub 2011/12/20)
221. U. Ramaswami, S. Wendt, G. Pintos-Morell, R. Parini, C. Whybra, and J.A. Leon Leal et al. Enzyme replacement therapy with agalsidase alfa in children with Fabry disease Acta Paediatr 96 1 2007 122 127 (Epub 2006/12/26)
222. Raphael Schiffmann, Peter Hauer, Barbara Freeman, Markus Ries, Leland J.C. Scott, and Michael Polydefkis et al. Enzyme replacement therapy and intraepidermal innervation density in Fabry disease Muscle Nerve 34 2006 53 56
223. R. Schiffmann, M.K. Floeter, J.M. Dambrosia, S. Gupta, D.F. Moore, and Y. Sharabi et al. Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease Muscle Nerve 28 6 2003 703 710 (Epub 2003/11/26)
224. M.J. Hilz, M. Brys, H. Marthol, B. Stemper, and M. Dutsch Enzyme replacement therapy improves function of C-, Adelta-, and Abeta-nerve fibers in Fabry neuropathy Neurology 62 7 2004 1066 1072 (Epub 2004/04/14)
225. L.B. Jardim, I. Gomes, C.B. Netto, D.B. Nora, U.S. Matte, and F. Pereira et al. Improvement of sympathetic skin responses under enzyme replacement therapy in Fabry disease J Inherit Metab Dis 29 5 2006 653 659 (Epub 2006/09/15)
226. R. Schiffmann, M.K. Floeter, J.M. Dambrosia, S. Gupta, D.F. Moore, and Y. Sharabi et al. Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease Muscle Nerve 28 2003 703 710
227. M.J. Hilz, M. Brys, H. Marthol, B. Stemper, and M. Dütsch Enzyme replacement therapy improves function of C-, Ad, and Ab-nerve fibers in Fabry neuropathy Neurology 62 2004 1066 1072
228. R. Schiffmann, P. Hauer, B. Freeman, M. Ries, L.J. Scott, and M. Polydefkis et al. Enzyme replacement therapy and intraepidermal innervation density in Fabry disease Muscle Nerve 34 1 2006 53 56 (Epub 2006/04/04)
229. W.R. Wilcox, M. Banikazemi, N. Guffon, S. Waldek, P. Lee, and G.E. Linthorst et al. Long-term safety and efficacy of enzyme replacement therapy for Fabry disease Am J Hum Genet 75 1 2004 65 74 (Epub 2004/05/22)
230. U. Ramaswami, S. Wendt, G. Pintos-Morell, R. Parini, C. Whybra, and J.A. Leon Leal et al. Enzyme replacement therapy with agalsidase alfa in children with Fabry disease Acta Paediatr 96 1 2007 122 127 (Epub 2006/12/26)
231. S.M. Rombach, B.E. Smid, M.G. Bouwman, G.E. Linthorst, M.G. Dijkgraaf, and C.E. Hollak Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain Orphanet J Rare Dis 8 2013 47
232. B. Hoffmann, M. Schwarz, A. Mehta, and S. Keshav Gastrointestinal symptoms in 342 patients with Fabry disease: prevalence and response to enzyme replacement therapy Clin Gastroenterol Hepatol 5 12 2007 1447 1453 (Epub 2007/10/09)
233. B. Hoffmann, D. Reinhardt, and B. Koletzko Effect of enzyme-replacement therapy on gastrointestinal symptoms in Fabry disease Eur J Gastroenterol Hepatol 16 10 2004 1067 1069 (Epub 2004/09/17)
234. S. Feriozzi, A. Schwarting, G. Sunder-Plassmann, M. West, and M. Cybulla Agalsidase alfa slows the decline in renal function in patients with Fabry disease Am J Nephrol 29 5 2009 353 361 (Epub 2008/11/01)
235. M. West, K. Nicholls, A. Mehta, J.T. Clarke, R. Steiner, and M. Beck et al. Agalsidase alfa and kidney dysfunction in Fabry disease J Am Soc Nephrol 20 5 2009 1132 1139 (Epub 2009/04/10)
236. T. Thomaidis, M. Relle, J. Reinke, M. Beck, and A. Schwarting Effect of enzyme replacement therapy (ERT) on renal function of patients with Fabry's disease Med Klin (Munich) 104 9 2009 699 703
237. Saskia M. Rombach, Bouwien E. Smid, Machtelt G. Bouwman, Gabor E. Linthorst, Marcel G.W. Dijkgraaf, and Carla E.M. Hollak Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain Orphanet J Rare Dis 8 2013 47
238. R. Schiffmann, H. Askari, M. Timmons, C. Robinson, W. Benko, and R.O. Brady et al. Weekly enzyme replacement therapy may slow decline of renal function in patients with Fabry disease who are on long-term biweekly dosing J Am Soc Nephrol 18 5 2007 1576 1583 (Epub 2007/04/06)
239. D.P. Germain, S. Waldek, M. Banikazemi, D.A. Bushinsky, J. Charrow, and R.J. Desnick et al. Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease J Am Soc Nephrol 18 5 2007 1547 1557 (Epub 2007/04/06)
240. B.L. Thurberg, H. Rennke, R.B. Colvin, S. Dikman, R.E. Gordon, and A.B. Collins et al. Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy Kidney Int 62 6 2002 1933 1946 (Epub 2002/11/13)
241. C.M. Eng, M. Banikazemi, R.E. Gordon, M. Goldman, R. Phelps, and L. Kim et al. A phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies Am J Hum Genet 68 3 2001 711 722 (Epub 2001/02/17)
242. F. Weidemann, M. Niemann, S. Störk, F. Breunig, M. Beer, and C. Sommer Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications J Intern Med 274 4 2013 331 341
243. C. Kampmann, A. Linhart, R.B. Devereux, and R. Schiffmann Effect of agalsidase alfa replacement therapy on Fabry disease-related hypertrophic cardiomyopathy: a 12- to 36-month, retrospective, blinded echocardiographic pooled analysis Clin Ther 31 9 2009 1966 1976
244. M. Ries, J.T. Clarke, C. Whybra, M. Timmons, C. Robinson, and B.L. Schlaggar et al. Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease Pediatrics 118 3 Sep 2006 924 932
245. F. Baehner, C. Kampmann, C. Whybra, E. Miebach, C.M. Wiethoff, and M. Beck Enzyme replacement therapy in heterozygous females with Fabry disease: results of a phase IIIB study J Inherit Metab Dis 26 7 2003 617 627 (Epub 2004/01/07)
246. C.M. Eng, N. Guffon, W.R. Wilcox, D.P. Germain, P. Lee, and S. Waldek et al. Safety and efficacy of recombinant human alpha-galactosidase A - replacement therapy in Fabry's disease N Engl J Med 345 1 2001 9 16 (Epub 2001/07/07)
247. R.J. Kalliokoski, I. Kantola, K.K. Kalliokoski, E. Engblom, J. Sundell, and J.C. Hannukainen et al. The effect of 12-month enzyme replacement therapy on myocardial perfusion in patients with Fabry disease J Inherit Metab Dis 29 1 2006 112 118 (Epub 2006/04/08)
248. F. Weidemann, F. Breunig, M. Beer, J. Sandstede, O. Turschner, and W. Voelker et al. Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study Circulation 108 11 2003 1299 1301 (Epub 2003/09/04)
249. F. Weidemann, M. Niemann, F. Breunig, S. Herrmann, M. Beer, and S. Störk et al. Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment Circulation 119 4 Feb 3 2009 524 529
250. M. Ries, J.T. Clarke, C. Whybra, M. Timmons, C. Robinson, and B.L. Schlaggar et al. Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease Pediatrics 118 3 2006 924 932
251. M. Ries, J.T. Clarke, C. Whybra, A. Mehta, K.S. Loveday, and R.O. Brady et al. Enzyme replacement in Fabry disease: pharmacokinetics and pharmacodynamics of agalsidase alpha in children and adolescents J Clin Pharmacol 47 10 2007 1222 1230 (Epub 2007/08/19)
252. J.E. Wraith, A. Tylki-Szymanska, N. Guffon, Y.H. Lien, M. Tsimaratos, and A. Vellodi et al. Safety and efficacy of enzyme replacement therapy with agalsidase beta: an international, open-label study in pediatric patients with Fabry disease J Pediatr 152 4 2008 563 570
253. Patrick B. Deegan, Frank Bähner, Miguel Barba, Derralynn A. Hughes, and Michael Beck Fabry disease in females: clinical characteristics and effects of enzyme replacement therapy Oxford Pharma Genesis 2006
254. S. Wendt, C. Whybra, C. Kampmann, E. Teichmann, and M. Beck Successful pregnancy outcome in a patient with Fabry disease receiving enzyme replacement therapy with agalsidase alfa J Inherit Metab Dis 28 5 2005 787 788 (Epub 2005/09/10)
255. G. Kalkum, D. Macchiella, J. Reinke, H. Kolbl, and M. Beck Enzyme replacement therapy with agalsidase alfa in pregnant women with Fabry disease Eur J Obstet Gynecol Reprod Biol 144 1 2009 92 93 (Epub 2009/02/24)
256. D.P. Germain, P. Bruneval, T.C. Tran, P. Balouet, B. Richalet, and K. Benistan Uneventful pregnancy outcome after enzyme replacement therapy with agalsidase beta in a heterozygous female with Fabry disease: a case report Eur J Med Genet 53 2 2010 111 112 (Epub 2010/01/05)
257. J.M. Politei Treatment with agalsidase beta during pregnancy in Fabry disease J Obstet Gynaecol Res 36 2 2010 428 429 (Epub 2010/05/25)
258. M. Beck, R. Ricci, U. Widmer, F. Dehout, A.G. de Lorenzo, and C. Kampmann et al. Fabry disease: overall effects of agalsidase alfa treatment Eur J Clin Investig 34 12 2004 838 844
259. Uma Ramaswami Update on role of agalsidase alfa in management of Fabry disease Drug Des Dev Ther 5 2011 155 173
260. T. Watt, A.P. Burlina, C. Cazzorla, D. Schonfeld, M. Banikazemi, and R.J. Hopkin et al. Agalsidase beta treatment is associated with improved quality of life in patients with Fabry disease: findings from the Fabry registry Genet Med 12 11 2010 703 712 (Epub 2010/10/05)
261. M. Banikazemi, J. Bultas, S. Waldek, W.R. Wilcox, C.B. Whitley, and M. McDonald et al. Agalsidase-beta therapy for advanced Fabry disease: a randomized trial Ann Intern Med 146 2 2007 77 86 (Epub 2006/12/21)
262. G.E. Linthorst, C.E. Hollak, W.E. Donker-Koopman, A. Strijland, and J.M. Aerts Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta Kidney Int 66 4 2004 1589 1595 (Epub 2004/10/02)
263. B. Benichou, S. Goyal, C. Sung, A.M. Norfleet, and F. O'Brien A retrospective analysis of the potential impact of IgG antibodies to agalsidase beta on efficacy during enzyme replacement therapy for Fabry disease Mol Genet Metab 96 1 2009 4 12 (Epub 2008/11/22)
264. G.E. Linthorst, C.E. Hollak, W.E. Donker-Koopman, A. Strijland, and J.M. Aerts Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta Kidney Int 66 4 2004 1589 1595
265. 3 reduction and treatment outcome PLoS ONE 7 10 2012 47805 10.1371/journal.pone.0047805 (Epub 2012 Oct 19)
266. T. Ohashi, S. Iizuka, H. Ida, and Y. Eto Reduced alpha-Gal A enzyme activity in Fabry fibroblast cells and Fabry mice tissues induced by serum from antibody positive patients with Fabry disease Mol Genet Metab 94 3 2008 313 318 (Epub 2008/05/06)
267. Johannes M. Aerts, Johanna E. Groener, Sijmen Kuiper, Wilma E. Donker-Koopman, Anneke Strijland, and Roelof Ottenhoff Elevated globotriaosylsphingosine is a hallmark of Fabry disease PNAS 105 8 2008 2812 2817
268. T. Togawa, T. Kodama, T. Suzuki, K. Sugawara, T. Tsukimura, and T. Ohashi Plasma globotriaosylsphingosine as a biomarker of Fabry disease Mol Genet Metab 100 3 2010 257 261
269. S.M. Rombach, N. Dekker, M.G. Bouwman, G.E. Linthorst, A.H. Zwinderman, and F.A. Wijburg et al. Plasma globotriaosylsphingosine: diagnostic value and relation to clinical manifestations of Fabry disease Biochim Biophys Acta 1802 9 2010 741 748
270. M.J. Van Breemen, S.M. Rombach, N. Dekker, B.J. Poorthuis, G.E. Linthorst, and A.H. Zwinderman et al. Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy Biochim Biophys Acta 1812 1 2011 70 76
271. T. Togawa, I. Kawashima, T. Kodama, T. Tsukimura, T. Suzuki, and T. Fukushige et al. Tissue and plasma globotriaosylsphingosine could be a biomarker for assessing enzyme replacement therapy for Fabry disease Biochem Biophys Res Commun 399 4 2010 716 720
272. R.Y. Wang, A. Lelis, J. Mirocha, and W.R. Wilcox Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life Genet Med 9 1 2007 34 45
273. D.P. Germain, K. Benistan, and L. Angelova X-linked inheritance and its implication in the diagnosis and management of female patients in Fabry disease Rev Med Interne 2 2010 209 213
274. A. Mehta, M.L. West, G. Pintos-Morell, R. Reisin, K. Nicholls, and L.E. Figuera et al. Therapeutic goals in the treatment of Fabry disease Genet Med 12 11 2010 713 720
275. G. Lenoir, M. Rivron, M.C. Gubler, J.L. Dufier, F.S. Tome, and M. Guivarch Fabry's disease. Carbamazepine therapy in acrodyniform syndrome Arch Fr Pediatr 34 8 1977 704 716
276. M.R. Filling-Katz, H.F. Merrick, J.K. Fink, R.B. Miles, J. Sokol, and N.W. Barton Carbamazepine in Fabry's disease: effective analgesia with dose-dependent exacerbation of autonomic dysfunction Neurology 39 4 1989 598 600 (Epub 1989/04/01)
277. D.P. Germain Fabry's disease (alpha-galactosidase-A deficiency): recent therapeutic innovations Maladie de Fabry (deficit en alpha-galactosidase A): innovations therapeutiques recentes J Soc Biol 196 2 2002 183 190 (Epub 2002/10/04)
278. M. Ries, E. Mengel, G. Kutschke, K.S. Kim, F. Birklein, and F. Krummenauer et al. Use of gabapentin to reduce chronic neuropathic pain in Fabry disease J Inherit Metab Dis 26 4 2003 413 414 (Epub 2003/09/16)
279. L.A. Lockman, D.B. Hunninghake, W. Krivit, and R.J. Desnick Relief of pain of Fabry's disease by diphenylhydantoin Neurology 23 8 1973 871 875 (Epub 1973/08/01)
280. C.M. Eng, D.P. Germain, M. Banikazemi, D.G. Warnock, C. Wanner, and R.J. Hopkin et al. Fabry disease: guidelines for the evaluation and management of multi-organ system involvement Genet Med 8 9 2006 539 548
281. A. Mehta, J.T. Clarke, R. Giugliani, P. Elliott, A. Linhart, and M. Beck et al. Natural course of Fabry disease: changing pattern of causes of death in FOS - Fabry Outcome Survey J Med Genet 46 8 2009 548 552 (Epub 2009/05/29)
282. T. Thomaidis, M. Relle, M. Golbas, C. Brochhausen, P.R. Galle, and M. Beck et al. Downregulation of alpha-galactosidase A upregulates CD77: functional impact for Fabry nephropathy Kidney Int 75 4 2009 399 407 Epub 2008/11/28
283. G.M. Pastores, and D.A. Hughes To see a world in a grain of sand: elucidating the pathophysiology of Anderson-Fabry disease through investigations of a cellular model Kidney Int 75 4 2009 351 353 Epub 2009/01/31
284. Y. Tajima, I. Kawashima, T. Tsukimura, K. Sugawara, M. Kuroda, and T. Suzuki et al. Use of a modified alpha-N-acetylgalactosaminidase in the development of enzyme replacement therapy for Fabry disease Am J Hum Genet 85 5 2009 569 580 Epub 2009/10/27
285. G.H. Yam, N. Bosshard, C. Zuber, B. Steinmann, and J. Roth Pharmacological chaperone corrects lysosomal storage in Fabry disease caused by trafficking-incompetent variants Am J Physiol Cell Physiol 290 4 2006 C1076 C1082 Epub 2006/03/15
286. G.H. Yam, C. Zuber, and J. Roth A synthetic chaperone corrects the trafficking defect and disease phenotype in a protein misfolding disorder FASEB J 19 1 2005 12 18 Epub 2005/01/05
287. J.Q. Fan, and S. Ishii Active-site-specific chaperone therapy for Fabry disease. Yin and Yang of enzyme inhibitors FEBS J 274 19 2007 4962 4971 Epub 2007/09/27
288. D.P. Germain, and J.Q. Fan Pharmacological chaperone therapy by active-site-specific chaperones in Fabry disease: in vitro and preclinical studies Int J Clin Pharmacol Ther 47 Suppl. 1 2009 S111 S117 Epub 2010/01/27
289. K. Sugawara, Y. Tajima, I. Kawashima, T. Tsukimura, S. Saito, and K. Ohno et al. Molecular interaction of imino sugars with human alpha-galactosidase: insight into the mechanism of complex formation and pharmacological chaperone action in Fabry disease Mol Genet Metab 96 4 2009 233 238 Epub 2009/02/03
290. Cranbury, N.J., Jan. 6, 2012 (Globe Newswire).
291. S.C. Jung, I.P. Han, A. Limaye, R. Xu, M.P. Gelderman, and P. Zerfas et al. Adeno-associated viral vector-mediated gene transfer results in long-term enzymatic and functional correction in multiple organs of Fabry mice Proc Natl Acad Sci U S A 98 5 2001 2676 2681 Epub 2001/02/28
292. H. Takahashi, Y. Hirai, M. Migita, Y. Seino, Y. Fukuda, and H. Sakuraba et al. Long-term systemic therapy of Fabry disease in a knockout mouse by adeno-associated virus-mediated muscle-directed gene transfer Proc Natl Acad Sci U S A 99 21 2002 13777 13782 Epub 2002/10/09
293. G. Parenti Treating lysosomal storage diseases with pharmacological chaperones: from concept to clinics EMBO 1 5 2009 268 279 Epub 2010/01/06
294. K. Ogawa, Y. Hirai, M. Ishizaki, H. Takahashi, H. Hanawa, and Y. Fukunaga et al. Long-term inhibition of glycosphingolipid accumulation in Fabry model mice by a single systemic injection of AAV1 vector in the neonatal period Mol Genet Metab 96 3 2009 91 96 (Epub 2008/12/19)